vbl
therapeutics
provide
update
oval
study
today
wainwright
annual
global
investment
conference
tel
aviv
israel
globe
newswire
vbl
therapeutics
nasdaq
vblt
present
today
corporate
overview
including
update
oval
pivotal
study
wainwright
annual
global
investment
conference
held
virtually
september
oval
trial
ovarian
cancer
continues
progress
well
third
study
participants
already
enrolled
said
dror
harats
md
chief
executive
officer
vbl
therapeutics
pleased
high
response
rate
seen
interim
analysis
march
continues
high
total
patient
population
date
blinded
data
becoming
mature
currently
see
good
correlation
recist
responses
well
preliminary
pfs
os
data
far
oval
blinded
data
recapitulate
seen
positive
phase
study
encouraging
presentation
details
date
today
tuesday
september
time
edt
webcast
link
vbl
vascular
biogenics
operating
vbl
therapeutics
clinical
stage
biopharmaceutical
company
focused
discovery
development
commercialization
treatments
areas
unmet
need
cancer
immune
inflammatory
indications
vbl
developed
three
platform
technologies
based
technology
targeting
newly
formed
blood
vessels
focus
cancer
technology
targeting
applications
lecinoxoids
family
indications
vbl
lead
oncology
product
candidate
ofranergene
obadenovec
targeted
agent
developed
treat
wide
range
solid
tumors
conveniently
administered
iv
infusion
every
weeks
observed
cancer
patients
demonstrated
activity
signals
comers
phase
trial
well
three
phase
studies
ofranergene
obadenovec
currently
studied
phase
potential
registration
trial
ovarian
cancer
forward
looking
statements
press
release
contains
statements
statements
statements
historical
fact
statements
often
indicated
terms
anticipate
believe
could
estimate
expect
goal
intend
look
forward
may
plan
potential
predict
project
would
similar
expressions
statements
may
include
limited
statements
regarding
programs
including
including
clinical
development
therapeutic
potential
clinical
results
statements
promises
guarantees
involve
substantial
risks
uncertainties
among
factors
could
cause
actual
results
differ
materially
described
projected
herein
include
uncertainties
associated
generally
research
development
clinical
trials
related
regulatory
reviews
approvals
risk
historical
clinical
trial
results
may
predictive
future
trial
results
impact
pandemic
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
clinical
results
financial
resources
last
long
anticipated
may
realize
expected
benefits
intellectual
property
protection
list
description
risks
uncertainties
risks
found
regulatory
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
subsequent
filings
sec
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
hereof
vbl
therapeutics
undertakes
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
investor
contact
michael
rice
lifesci
advisors
llc
